Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …

Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD).
The non-invasive quantification of liver fat is now possible due to advances in imaging …

OBJECTIVE Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver
fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 …